GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Joinn Laboratories (China) Co Ltd (SHSE:603127) » Definitions » Piotroski F-Score

Joinn Laboratories (China) Co (SHSE:603127) Piotroski F-Score : 3 (As of Dec. 13, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Joinn Laboratories (China) Co Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Joinn Laboratories (China) Co has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Joinn Laboratories (China) Co's Piotroski F-Score or its related term are showing as below:

SHSE:603127' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 9
Current: 3

During the past 12 years, the highest Piotroski F-Score of Joinn Laboratories (China) Co was 9. The lowest was 3. And the median was 5.


Joinn Laboratories (China) Co Piotroski F-Score Historical Data

The historical data trend for Joinn Laboratories (China) Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Joinn Laboratories (China) Co Piotroski F-Score Chart

Joinn Laboratories (China) Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 6.00 6.00 3.00 5.00

Joinn Laboratories (China) Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 5.00 4.00 6.00 3.00

Competitive Comparison of Joinn Laboratories (China) Co's Piotroski F-Score

For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Joinn Laboratories (China) Co's Piotroski F-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Joinn Laboratories (China) Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Net Income was 69.394 + -272.222 + 102.48 + 99.436 = ¥-1 Mil.
Cash Flow from Operations was 174.435 + 119.954 + 37.763 + 34.609 = ¥367 Mil.
Revenue was 789.407 + 324.809 + 524.547 + 485.8 = ¥2,125 Mil.
Gross Profit was 318.162 + 106.652 + 151.281 + 108.971 = ¥685 Mil.
Average Total Assets from the begining of this year (Sep23)
to the end of this year (Sep24) was
(10232.67 + 10027.16 + 9733.254 + 9661.274 + 9525.185) / 5 = ¥9835.9086 Mil.
Total Assets at the begining of this year (Sep23) was ¥10,233 Mil.
Long-Term Debt & Capital Lease Obligation was ¥33 Mil.
Total Current Assets was ¥5,334 Mil.
Total Current Liabilities was ¥1,299 Mil.
Net Income was 442.224 + 187.76 + -97.133 + 236.971 = ¥770 Mil.

Revenue was 991.578 + 369.386 + 642.691 + 575.002 = ¥2,579 Mil.
Gross Profit was 451.9 + 190.956 + 257.612 + 246.057 = ¥1,147 Mil.
Average Total Assets from the begining of last year (Sep22)
to the end of last year (Sep23) was
(10079.079 + 10364.215 + 10548.084 + 10219.31 + 10232.67) / 5 = ¥10288.6716 Mil.
Total Assets at the begining of last year (Sep22) was ¥10,079 Mil.
Long-Term Debt & Capital Lease Obligation was ¥56 Mil.
Total Current Assets was ¥7,248 Mil.
Total Current Liabilities was ¥1,690 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Joinn Laboratories (China) Co's current Net Income (TTM) was -1. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Joinn Laboratories (China) Co's current Cash Flow from Operations (TTM) was 367. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep23)
=-0.91199999999998/10232.67
=-8.913E-5

ROA (Last Year)=Net Income/Total Assets (Sep22)
=769.822/10079.079
=0.07637821

Joinn Laboratories (China) Co's return on assets of this year was -8.913E-5. Joinn Laboratories (China) Co's return on assets of last year was 0.07637821. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Joinn Laboratories (China) Co's current Net Income (TTM) was -1. Joinn Laboratories (China) Co's current Cash Flow from Operations (TTM) was 367. ==> 367 > -1 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep23 to Sep24
=32.772/9835.9086
=0.00333187

Gearing (Last Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=56.149/10288.6716
=0.00545736

Joinn Laboratories (China) Co's gearing of this year was 0.00333187. Joinn Laboratories (China) Co's gearing of last year was 0.00545736. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep24)=Total Current Assets/Total Current Liabilities
=5334.112/1298.707
=4.10724821

Current Ratio (Last Year: Sep23)=Total Current Assets/Total Current Liabilities
=7248.202/1690.353
=4.28798127

Joinn Laboratories (China) Co's current ratio of this year was 4.10724821. Joinn Laboratories (China) Co's current ratio of last year was 4.28798127. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Joinn Laboratories (China) Co's number of shares in issue this year was 867.546. Joinn Laboratories (China) Co's number of shares in issue last year was 723.173. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=685.066/2124.563
=0.32245031

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1146.525/2578.657
=0.44462098

Joinn Laboratories (China) Co's gross margin of this year was 0.32245031. Joinn Laboratories (China) Co's gross margin of last year was 0.44462098. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep23)
=2124.563/10232.67
=0.20762548

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep22)
=2578.657/10079.079
=0.25584252

Joinn Laboratories (China) Co's asset turnover of this year was 0.20762548. Joinn Laboratories (China) Co's asset turnover of last year was 0.25584252. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+0+1+1+0+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Joinn Laboratories (China) Co has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Joinn Laboratories (China) Co  (SHSE:603127) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Joinn Laboratories (China) Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Joinn Laboratories (China) Co Business Description

Traded in Other Exchanges
Address
A5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, CHN, 100176
Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.
Executives
Yao Da Lin Director
Sun Yun Xia Director
Zuo Cong Lin Director
Gao Da Peng Director
Li Ye Supervisors
Gu Xiao Lei Director
Feng Yu Xia Director
Gu Jing Liang senior management
Yu Ai Shui senior management
Yin Li Li Supervisors
Sun Hui Ye Supervisors
Gu Mei Fang Director

Joinn Laboratories (China) Co Headlines

No Headlines